Tempest Therapeutics Inc (TPST)
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancer. Its lead candidates include Amezalpat, an oral selective antagonist of peroxisome proliferator-activated receptor alpha being studied for first-line unresectable or metastatic hepatocellular carcinoma, and TPST-1495, a dual antagonist of the EP2 and EP4 receptors in prostaglandin E2 for use across multiple cancer types. The company also has a collaboration with F. Hoffmann-La Roche Ltd. to advance Amezalpat into a global first-line randomized study. Tempest Therapeutics is headquartered in Brisbane, California, and its common stock trades on the NASDAQ under the symbol TPST.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TPST
|
$0.88
|
-12.3% Downside
|
Fair
|
$11 1,000.0% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
November 11, 2026
|
16.54 M
|
23.321 M
|
37.1%
|
69.3%
|
-47.1
|
51.2%
|
